Overview Fundamentals API Earnings EOD API Sample Code Pricing

MacroGenics Inc (MGNX NASDAQ) stock market data APIs

$4.68 -0.02(-0.4%) as of July 12, 2024
Price chart is built with Anychart

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

MacroGenics Inc Financial Data Overview

4.7
4.68
-
4.95
4.62
3.14-21.88
294 M
62 634 K
43 357 K
-0.84
2.074
Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'MGNX',
Type: 'Common Stock',
Name: 'MacroGenics Inc',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000BM2SF8',
ISIN: NULL,
CUSIP: NULL,
CIK: '1125345',
EmployerIdNumber: '06-1591613',
FiscalYearEnd: 'December',
IPODate: '2013-10-10',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

MacroGenics Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 43 357 K
  • EBITDA -175 064 992
  • Earnings Per Share -0.38
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get MacroGenics Inc Earnings via APIs

  • Latest Release 2024-05-09
  • EPS/Forecast -0.64

Get MacroGenics Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?
support@eodhistoricaldata.com